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INTRODUCTION
explored the acquisition of mutations in a set of 168 chromosomal genes, here defined as the 136 resistome, which have been described to be involved in P. aeruginosa antibiotic resistance 137 mechanisms (27, 28, 32) . Thus, using the 1991 genome as reference, we analyzed the distribution 138 of a total of 5710 SNPs and 1078 indels accumulated in a period of 20 years of infection, which 139 we have previously detected in the collection of isolates by WGS analysis (24) . Furthermore, we 140 also analyzed 39 SNPs (26 synonymous, 13 non-synonymous) detected in the genome sequence 141 of the 1991 isolate when compared to the PAO1 genome. Sequence variations found within the 142 resistome are documented in Supplementary Table 1 (Table S1 ). Interestingly, 93 (55%) of the 143 168 investigated genes, showed non-synonymous SNPs and/or indels mutations of 1-3 bp in at 144 least one of the isolates. On the other hand, 11 (6%) genes showed only synonymous mutations, 145 and 64 (38%) showed no mutations ( Fig. S1 ). Furthermore, 86 out of the 87 genes harboring non-146 synonymous mutations (99%), were targeted with missense mutations, whereas a single gene (1%) 147 showed a nonsense mutation ( Fig. S1 and Table S1 ). By analyzing the ratio between non-148 synonymous and synonymous mutations (dN/dS ratio) within the resistome in each CFD isolate 149 (Table S2) , we observed that in most isolates the signature of selection was higher than 1 and 150 higher than the ratio obtained from SNPs affecting all the other genes (dN/dS=0.78). This indicates 151 that these mutations were positively selected during chronic infection, and suggests that 152 hypermutability may be linked to them as a key factor contributing to antibiotic resistance in CF. Mutational resistome analysis was further focused on those genes that were targeted with non-154 synonymous and/or frameshift mutations (Fig. 3) , showing that accumulation of these mutations 155 correlated with increased antibiotic resistance. Moreover, no mutations were detected in the 156 ancestral 1991 isolate respect to the reference strain PAO1, in agreement with its general antibiotic 157 susceptibility (Fig. 2) . In some genes known to be involved in antibiotic resistance, single 158 mutations were identified, such as D87G in GyrA and S278P in OprD (33, 34) ; in others, the 159 accumulation of 3 to 5 different mutational events suggests that they have evolved under strong 160 selective pressure. Such examples are amgS, mexX, fusA2 (involved in aminoglycoside resistance), 161 mexF, oprN, poxB, mexI (involved in β-lactams resistance), polB, mexD, parE (involved in 162 quinolone resistance), spuF (polyamines) and mexK (coding for a novel efflux system MexJK) 163 (35). Remarkably, mexY, fusA1 (aminoglycoside resistance), ampC and ftsI (β-lactams resistance) 164 accumulated more than 6 different mutations ( Fig. 3) , providing strong evidence for parallel 165 evolution.
166
The β-lactam resistome. As shown in Fig. 1 , patient CFD received prolonged antibiotic courses 167 with Ceftazidime as well as shorter courses of varying durations with different types of β-lactams, 168 including other cephalosporins (Cefotaxime), penicillins (Piperacillin + tazobactam), 169 monobactams (Aztreonam) and carbapenems (Thienamycin and Meropenem). As expected, 170 resistance increased from the 1995 isolate to later isolates, reaching the highest resistance levels 171 to cephalosporins, aztreonam and carbapenems in the 2011 isolates ( Fig. 2 ). A total of 70 genes 172 have been reported to be involved in the β-lactam resistome (27, 28) , including: regulation of 173 peptidoglycan-recycling genes (responsible for AmpC overproduction), genes encoding penicillin-174 binding proteins (PBPs, targets of β-lactam antibiotics), or encoding regulators of efflux pumps 175 such as mexAB-oprM (involved in β-lactam resistance) and mexEF-OprN (involved in 176 carbapenem resistance) and, the oprD gene (involved in resistance to imipenem and susceptibility 177 9 to meropenem). We found that 42 of these 70 genes (60%) showed non-synonymous and/or 178 frameshift mutations in at least one isolate of the CFD collection ( Fig. 3 ). Of these 42 genes, 36 179 showed accumulations of 1 to 2 mutations, most of them being unique to each specific cluster. It 180 has been described that the emergence of resistance to penicillins and cephalosporins is mainly 181 due to overproduction of the β-lactamase AmpC (36). However, the most frequent drivers of 182 AmpC overproduction described in P. aeruginosa clinical strains, namely ampD, ampR and dacB 183 (37-39), were not mutated among CFD isolates. Instead, all but the 1991 isolate showed a 184 frameshift mutation in mpl, which encodes a UDP-N-acetylmuramate:l-alanyl-γ-d-glutamyl-meso-185 diaminopimelate ligase, indicating that ampC could be overexpressed via this alternative negative 186 regulator (40). Western blot analyses showed that all 2011 isolates showed an increased expression 187 of AmpC compared to the 1991, 1995 and 2002 isolates, suggesting that alternative pathways may 188 be responsible for AmpC overproduction in these isolates (Fig. S2 ). In addition, ampC was among 189 the most mutated genes in the CFD collection together with the ftsI gene, showing 8 and 13 distinct 190 missense mutations, respectively ( Fig. 3) . In fact, all CFD isolates, except 1991 and 1995, showed indicating that they were under high selective pressure during the CFD chronic infection process.
195
Interestingly, the presence of mutations such as P154L, G216S and V213A, has been reported to 196 be involved in β-lactam resistance (41). Likewise, all isolates except for 1991 showed mutations 197 in ftsI, compared with isolates from 2011 showing up to six mutations combined in a single allele.
198
Some of these mutations (Y367C, H394R, N427S, Q458R, Q475R, R504L, V523A, V523M and 199 F533L) are located in the transpeptidase β-lactam binding site of the protein, and the latter mutation 200 has been shown to play a key role in β-lactam recognition (42). Importantly, these mutations have 201 10 been documented to emerge among P. aeruginosa CF collections (28, 43, 44) and upon aztreonam 202 exposure in vitro (45), whereas other mutations are described for the first time in this work ( Table   203   S1 ). The rest of the PBP encoding genes showed few mutations among the CFD collection.
204
Although patient CFD received only short courses with carbapenems, we observed the emergence 205 of high levels of resistance to carbapenems in all isolates except for the ancestral 1991 isolate. showed in Figure 2 ) showed a missense mutation (S278P) within the oprD gene, which has been 211 previously described to be involved in carbapenem resistance (34). Expression of the MexAB-212 oprM system is controlled by the regulatory genes mexR, nalC and nalD (46, 47), and a missense 213 mutation in nalC (M151T) was identified in the two isolates from Cluster V. Mutations F533L and 214 R504 in PBP3 have been found to occur upon meropenem exposure during in vitro evolution 215 studies and among CF patients treated with this drug (44, 48). Thus, high levels of carbapenem 216 resistance may be associated with the presence of these ftsI mutations. Importantly, using 217 ResFinder tool on WGS data from CFD isolates, we did not find genes coding for any class of β 218 Metallo-beta-lactamases (MBLs) involved in carbapenem resistance, which are normally acquired 219 through horizontal gene transfer (49). These results suggest that various different mutational 220 mechanisms may be involved in carbapenem resistance in different coexisting CFD isolates, giving 221 rise to distinct genetic pathways for the evolution of resistance to β-lactams. (50), which is primarily caused by mexZ mutations 226 (10, 21, 51). In addition, mutations in the amgRS and parRS two-component systems genes have 227 also been involved in the regulation of MexXY expression (52). No mexZ mutations, however, 228 were observed in the CFD collection of isolates, with the sole exception of isolate 2011_33 (Cluster 229 VI), which showed a V29A mutation located within the DNA binding domain of the protein (Table   230 S1) (53) and predicted to be deleterious (-3.351 PROVEAN v1.1.3). Instead, we found four 231 different mutations in gene amgS, encoding the histidine kinase sensor of the membrane stress-232 response two-component system, six mutations in mexY, encoding a component of the MexXY 233 efflux pump, and six mutations in fusA1, which codes for the elongation factor G. 234 MexY mutations have been frequently observed among drug-resistance isolates and CF epidemic 235 clones (28, 31). Some mutations affect the general pump operation and impair the MexY-236 dependent aminoglycoside resistance, whereas other mutations, located in domains associated with 237 aminoglycoside recognition and export, may improve drug accommodation and consequently 238 increase resistance (54). Furthermore, it was observed that the MexY mutation F1018L is able to 239 increase pump-promoted resistance to aminoglycosides, cefepime, and fluoroquinolones (55).
240
Importantly, here we describe for the first time the six mexY missense mutations. In this sense, 241 their impact in MexXY pump function and aminoglycoside resistance remains unclear and 242 deserves further investigation.
243
Mutations in the amgS gene have been shown to be involved in intrinsic aminoglycoside resistance 244 in P. aeruginosa (56) . Although none of the four mutations in amgS found here have been 245 previously reported (Table S1 ), all isolates from 2011 except 2011_33 showed an A203V mutation 246 located within the linker HAMP domain. Interestingly, it has been reported that mutations in the 247 linker domain of EnvZ, the closest E. coli homolog of AmgS, often cause activation of the kinase 248 sensor (57, 58). Moreover, we found the P116L mutation, predicted to be deleterious (-2.539 249 12 PROVEAN v1.1.3). This mutation is located in the sensor domain of AmgS, where mutations 250 involved in aminoglycoside resistance have been previously described (56).
251
FusA1 mutations have been recently linked to the emergence of aminoglycoside resistance in vitro 252 (59-61) as well as in clinical CF strains (28, (62) (63) (64) . In fact, aminoglycoside resistance seems to 253 be an indirect consequence of the alteration of elongation factor G (60). Isolate 2011_34 harbored 254 two substitutions, V93A and D588G, located in domains G and IV of the protein, respectively, 255 which have been reported to be gain-of-function mutations (28). Indeed, the V93A mutation was 256 found to increase resistance to several aminoglycosides such as tobramycin, amikacin, and 257 gentamycin (60). In several CFD isolates we identified four novel mutations in the fusA1 gene 258 across the different domains of the protein sequence: domain II (V338A), domain III (A481V), 259 domain IV (A595V) and domain V (Y683C). Isolate 1995, harboring the Y683C mutation, showed 260 susceptibility to tobramycin (Fig. 2 ), suggesting that this mutation is not involved in subunits of topoisomerase IV (28). Indeed, all CFD isolates except for the 1991, harbored the same 275 D87G mutation in GyrA. In addition, isolate 2011_33 also carried a T83I mutation in this gyrase 276 subunit. Importantly, both mutations are known to be involved in quinolone resistance (28, 31, 277 33). Furthermore, two 2011 isolates from Cluster IV harbored an S618L substitution in GyrB. On 278 the other hand, all isolates except for the 1991, accumulated mutations in the topoisomerase IV 279 subunits ParC (P308L, T705A) and ParE (V199M, D462G, S492F), none of which have been 280 previously described. Whether these mutations clustered in the chromosomally encoded 281 topoisomerases II and IV were involved in quinolone resistance or were randomly fixed by genetic 282 drift upon the high mutation supplies provided by hypermutability, remains to be elucidated.
283
Nevertheless, the fact that many different mutations arose after fluoroquinolone treatments 284 supports the previous observation that mutations involved in fluoroquinolone resistance can be 285 highly variable (28). Importantly, with the use of the ResFinder tool we found the acquisition of a Finally, we noticed that no mutations were observed in the negative regulator nfxB among the CFD 290 isolates, which is commonly reported to achieve resistance to ciprofloxacin in a CF context due to 291 the deregulation and concomitant overexpression of the efflux pump MexCD-OprJ (66).
292
Furthermore, although all Cluster IV isolates from 2011 harbored a nonsense mutation in the 293 transporter MexD (W1023STOP), which inactivates the efflux pump, it has been described that 294 this mutation has no effect on the MIC of ciprofloxacin (67).
295
The polymyxin resistome. Patient CFD received intensive treatment with colistin from 2004 to 296 2011 ( Fig. 1) . According to CLSI, antibiotic susceptibility profiling revealed that every CFD 297 14 isolate was resistant to colistin (Fig. 2) . However, the evolved 2011 isolates from cluster III, IV 298 and V as well as the 2002 isolate, showed 2-to 4-fold increases in their MICs relative to 1991 and 299 1995 isolates (8 μg/mL) (Fig. 2) . Clinical strains of P. aeruginosa sometimes show resistance to 300 polymyxins due to mutations in different two-component systems, such as PhoPQ, PmrAB, ParRS, whereas the remaining isolates from 2011 carried a C2597T mutation, both located in the 322 secondary structure of domain V of the ribosomal RNA gene and previously reported to confer 323 macrolide resistance (32, 75) . Thus, macrolide resistance in coexisting CFD 2011 isolates was 324 acquired by distinct mutations in the same gene. This provides additional evidence for parallel 325 molecular evolution at population level, with antibiotic chemotherapy as the key selection force 326 during long-term CF chronic infections.
327

DISCUSSION
328
The high prevalence of hypermutator clones in CF chronic infections is a matter of great relevance 329 because their link to antibiotic resistance hampers infection management (8-10, 14, 24, 76) . In this 330 study, we explored the evolution of the mutational antibiotic resistome of a P. aeruginosa 
338
Hypermutators can be indirectly selected for and fixed by their genomic association with fitness-339 improving alleles (77-80). Particularly, under selective conditions imposed by long-term antibiotic 340 therapy in the CF airways, de novo beneficial mutations can be expected to accumulate over time.
341
Early mutational events occurring during the course of long-term infection are expected to have a 342 strong impact on the resistance phenotype and consequently on fitness. Later mutations, many of 343 them compensatory, may lead to fine tuning of the activity/stability of the resistance related 344 proteins, in which epistatic interactions may play important roles for the trajectories of resistance 345 development (81-84). P. aeruginosa carries many different genes, which upon functional 346 mutations provide a resistance phenotype (27, 28) . Identification of these genes and the associated 347 polymorphisms involved in resistance document how many of them converge through distinct 348 genetic pathways to the same or similar resistance profiles (26, 85, 86) .
349
Hypermutability increases the likelihood of reaching the most appropriate combinations in 350 adaptive terms. Considering the multiple genetic pathways in P. aeruginosa behind different 351 resistance mechanisms, our observations show how hypermutability increases the probability of 352 exploiting these distinct pathways, which eventually converge towards antibiotic multi-resistance 353 in the course of long-term chronic infections. 354 We show how aggressive and persistent chemotherapy targeting a hypermutator population 355 resulted in repeated but independent mutagenic events in resistance associated genes, providing 356 clear evidence of parallel evolution in clones of the CFD population. This was for example the 357 case with ampC and fstI, which for the CFD lineage constituted hot spots for the accumulation of 358 mutations involved in β-lactam antibiotic resistance (39, 41, 48, 49) . Some of these mutations have 359 been previously described, whereas others are reported here for the first time. Most interestingly, 360 novel alleles were observed, each harboring a combination of 2 to 6 mutations.
361
Overproduction of the β-lactamase AmpC is considered to be the main cause of resistance to first-362 and second-generation cephalosporins as well as aminopenicillins in P. aeruginosa clinical strains 363 (36). However, P. aeruginosa is also able to adapt to new and more effective β-lactams (87), 364 through a variety of mutations affecting the AmpC β-lactamase (41, 48, 88) . Here, we document 365 the confluence of both strategies: variants overproducing AmpC, in which the combination of 366 distinct mutations may contribute to even higher levels of resistance and/or substrate spectrum 367 extension. Furthermore, the accumulation of several different mutations in the penicillin-binding 368 protein PBP3 may be a complementary and/or additional pathway. PBP3 relevance in β-lactam 369 resistance, including the new generation cephalosporins and carbapenems, has been very recently 370 confirmed (27, 28, 31, 43, 48) . The high number of different mutations clustered in both ampC 371 and fstI genes combines into innovative resistance-conferring alleles, which demonstrate how 372 drug-resistance mutations can become highly beneficial when combined with compensatory 373 mutations, and thus document the extraordinary ability of P. aeruginosa to develop antibiotic 374 resistance. In this context, the emergence of such innovative alleles may be distinctly favored by 375 hypermutator phenotypes, then limiting our available therapeutic arsenal.
376
How can we understand co-existence of many different genetic variants showing the same 377 resistance profile in patient airways, such as it has been documented here? One answer is based on 378 the balance between clonal interference and multiple mutations (89, 90) . We thus argue that 379 hypermutability increases the rate of antibiotic resistance evolution by increasing piggy-backing 380 of multiple resistance mutations, causing maintenance of a diversified population where adaptive 381 variation is sustained by a dynamic equilibrium between mutation and selection. Moreover, in 382 long-term evolutionary scenarios such as chronic infections, the selective forces imposed by 383 antibiotics along with high mutation rates from hypermutability, may shape genetically diverse 384 populations able to respond successfully to antibiotic treatments ensuring persistence of the 385 bacterium. Figure S1 . Analysis of type of mutations found in antibiotic resistance genes in P. aeruginosa 789 isolates from CFD patient. 790 Pie charts indicate the observed percentage for each kind of mutation respect to the total number 791 of mutations occurring in the 168 belonging to the P. aeruginosa resistome. 792 Figure S2 . Western blot of CFD isolates. 793 Total proteins (25μg) were obtained from whole-cell lysates from each P. aeruginosa clinical 794 isolates, resolved in a 12% polyacrylamide gel, and tested with a PDC-3 antibody.
795
Table S1. Nonsynonymous and frameshift mutations found within 93 out of 168 antibiotic 796 resistance genes in CFD collection. 797   Table S2 . Number of genes mutated and type of mutations found in the sequenced 798 genomes.
